Ensysce Biosciences Inc. News

Aktie

WKN: A3D9Z4 ISIN: US2936024056 US-Symbol: ENSC

0,5887 $

+0,0171 $

+2,99%

31.05.24 20:35:28

Handeln Depot/Watchlist

Aktienanzahl *

3,15 Mio.

Marktkapitalisierung *

1,67 Mio. €

Streubesitz

Index-Zugehörigkeit

IR-Website

zur Website

*Stand: 26.01.2024

Ensysce Biosciences Inc. News

03.07.23 - PR Newswire

Thinking about buying stock in Marathon Digital Holdings, Kartoon Studios, Aurora Innovation, Nikola, or Ensysce Biosciences?

Thinking about buying stock in Marathon Digital Holdings, Kartoon Studios, Aurora Innovation, Nikola, or Ensysce Biosciences? PR Newswire

25.01.23 - PR Newswire

Thinking about buying stock in Esports Entertainment, Faraday Future Intelligent Electric, Ensysce Biosciences, NVIDIA, or Mullen Automotive?

Thinking about buying stock in Esports Entertainment, Faraday Future Intelligent Electric, Ensysce Biosciences, NVIDIA, or Mullen Automotive? PR Newswire

26.10.22 - PR Newswire

Thinking about buying stock in SINTX Technologies, Ensysce Biosciences, Nio, Canopy Growth Corp, or Marathon Digital?

Thinking about buying stock in SINTX Technologies, Ensysce Biosciences, Nio, Canopy Growth Corp, or Marathon Digital? PR Newswire

22.09.22 - ACCESSWIRE

Ensysce Biosciences Announces Initiation of Second Human Abuse Potential Study, Being Conducted by DVCR

~ Oral Opioid Abuse Being Explored for PF614 ~

21.09.22 - ACCESSWIRE

Ensysce Biosciences to Present at Benzinga All Access Event on Friday, September 23, 2022

SAN DIEGO, CA / ACCESSWIRE / September 21, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech ...

14.09.22 - PR Newswire

Thinking about buying stock in Altimmune, Transocean, Cleveland-Cliffs, Ensysce Biosciences, or Kiora Pharmaceuticals?

Thinking about buying stock in Altimmune, Transocean, Cleveland-Cliffs, Ensysce Biosciences, or Kiora Pharmaceuticals? PR Newswire

08.09.22 - ACCESSWIRE

Ensysce Biosciences Announces Results of Special Meeting of Stockholders

SAN DIEGO, CA / ACCESSWIRE / September 8, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech ...

06.09.22 - ACCESSWIRE

Ensysce Biosciences Reminds Shareholders to Vote at Upcoming Special Meeting

~ Special Meeting to be Held Virtually on Thursday, September 8 th at 9:00 AM PT ~

31.08.22 - PR Newswire

Ensysce Biosciences and Quotient Sciences Announce a Partnership on the Development and Clinical Testing of Ensysce's PF614-MPAR, a Novel Opioid Designed to Prevent Abuse and Overdose

Ensysce Biosciences and Quotient Sciences Announce a Partnership on the Development and Clinical Testing of Ensysce's PF614-MPAR, a Novel Opioid Designed to Prevent ...

31.08.22 - PR Newswire

Ensysce Biosciences and Quotient Sciences Announce a Partnership on the Development and Clinical Testing of Ensysce's PF614-MPAR, a Novel Opioid Designed to Prevent Abuse and Overdose

Ensysce Biosciences and Quotient Sciences Announce a Partnership on the Development and Clinical Testing of Ensysce's PF614-MPAR, a Novel Opioid Designed to Prevent ...

31.08.22 - ACCESSWIRE

Ensysce Biosciences Debuts Redesigned Company Website to Highlight its TAAP(TM) and MPAR(TM) Technologies and Growing Product Pipeline

SAN DIEGO, CA / ACCESSWIRE / August 31, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech ...

24.08.22 - ACCESSWIRE

Ensysce Biosciences, Inc. Announces Participation in Upcoming Conferences

SAN DIEGO, CA / ACCESSWIRE / August 24, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC) (OTC:ENSCW), a clinical-stage biotech company ...

23.08.22 - ACCESSWIRE

Ensysce Biosciences Announces Completion of Clinical Portion of Human Abuse Potential Trial PF614-103

Completion of Clinical Portion Represents Critical Milestone Towards Commercialization

17.08.22 - ACCESSWIRE

Ensysce Biosciences Releases Updated Investor Presentation Ahead of Corporate Update Call

~ Call to be Held Today, August 17, 2022 at 11am ET ~

11.08.22 - ACCESSWIRE

Ensysce Biosciences Provides Business Update and Reports Second Quarter 2022 Financial Results

Corporate Update Call to be Held Wednesday, August 17, 2022

09.08.22 - ACCESSWIRE

Ensysce Biosciences Announces Completion of $8 Million Convertible Note Financing

SAN DIEGO, CA / ACCESSWIRE / August 9, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC, OTC PINK:ENSCW), a clinical-stage biotech company ...

27.07.22 - ACCESSWIRE

Ensysce Biosciences Announces Positive Bioequivalence (BE) Study Data of Novel "TAAP" Opioid PF614 and Provides Timing of Corporate Update Call

~ BE Study of PF614 Represents Critical Progress Toward FDA Approval ~ ~ Supports the 505(b)(2) Regulatory Path for Clinical Development of PF614 ~ SAN DIEGO, CA / ...

13.07.22 - ACCESSWIRE

Ensysce Biosciences Announces Initial Patients Dosed of First Human Abuse Potential Study

~ Trial Designed to Test and Confirm Nasal Opioid Manipulation ~

01.07.22 - ACCESSWIRE

Ensysce Biosciences Secures $8 Million Convertible Note Financing

~ Additional Funding from Investor Cohort Validates Company's Mission ~

27.06.22 - ACCESSWIRE

Ensysce Biosciences Receives Notice of Award for 4th Year of Funding for Its Multi-Pill Abuse Resistance (MPAR(TM)) Platform

SAN DIEGO, CA / ACCESSWIRE / June 27, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC) (OTC:ENSCW), a clinical-stage biotech company ...

Newssuche

Videos

29.05.24

Technical Trading: DAX Long Chance kurzfristig

DAX Long Typ: Turbo Open End WKN: VD5FWS Hebel: 28 Laufzeit: OpenEnd Einstieg: Market ... Mehr »

Weitere Videos